Opinion|Videos|November 18, 2026

Sequencing All-Comer Regimens After First-Line EGFR Therapy

Ticiana Leal, MD, of Winship Cancer Institute of Emory University, asks Julia Rotow, MD, of Dana-Farber Cancer Institute, how she sequences amivantamab-based regimens and datopotamab deruxtecan after first-line EGFR therapy in EGFR-mutant non–small cell lung cancer.

Ticiana Leal, MD, of Winship Cancer Institute of Emory University, asks Julia Rotow, MD, of Dana-Farber Cancer Institute, how she sequences amivantamab-based regimens and datopotamab deruxtecan after first-line EGFR therapy in EGFR-mutant non–small cell lung cancer. Dr Rotow reprofiles every patient for a targetable resistance mechanism, and when none is found, she chooses an all-comer regimen based on the first-line treatment. After osimertinib monotherapy, she considers amivantamab plus platinum doublet chemotherapy, based on MARIPOSA-2, the most guideline-concordant choice, and uses osimertinib plus chemotherapy, based on COMPEL, when disease, including central nervous system disease, is still largely controlled by targeted therapy. After amivantamab plus lazertinib, she usually gives a platinum doublet. After osimertinib plus chemotherapy, she most often turns to an antibody-drug conjugate, generally datopotamab deruxtecan, based on TROPION-Lung01 and TROPION-Lung05, or off-label amivantamab plus lazertinib when she wants an EGFR tyrosine kinase inhibitor on board.


Related to this article